-
1
-
-
0028970609
-
Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions
-
C. Albanese, J. Johnson, G. Watanabe, N. Eklund, D. Vu, and A. Arnold Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions J Biol Chem 270 1995 23589 23597
-
(1995)
J Biol Chem
, vol.270
, pp. 23589-23597
-
-
Albanese, C.1
Johnson, J.2
Watanabe, G.3
Eklund, N.4
Vu, D.5
Arnold, A.6
-
2
-
-
84865843828
-
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway
-
C. Andreadi, L.K. Cheung, S. Giblett, B. Patel, H. Jin, and K. Mercer The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway Genes Dev 26 2012 1945 1958
-
(2012)
Genes Dev
, vol.26
, pp. 1945-1958
-
-
Andreadi, C.1
Cheung, L.K.2
Giblett, S.3
Patel, B.4
Jin, H.5
Mercer, K.6
-
4
-
-
77956904045
-
Recurrent BRAF mutations in Langerhans cell histiocytosis
-
G. Badalian-Very, J.A. Vergilio, B.A. Degar, L.E. MacConaill, B. Brandner, and M.L. Calicchio Recurrent BRAF mutations in Langerhans cell histiocytosis Blood 116 2010 1919 1923
-
(2010)
Blood
, vol.116
, pp. 1919-1923
-
-
Badalian-Very, G.1
Vergilio, J.A.2
Degar, B.A.3
Macconaill, L.E.4
Brandner, B.5
Calicchio, M.L.6
-
5
-
-
77955090106
-
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
-
J. Barretina, B.S. Taylor, S. Banerji, A.H. Ramos, M. Lagos-Quintana, and P.L. Decarolis Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy Nat Genet 42 2010 715 721
-
(2010)
Nat Genet
, vol.42
, pp. 715-721
-
-
Barretina, J.1
Taylor, B.S.2
Banerji, S.3
Ramos, A.H.4
Lagos-Quintana, M.5
Decarolis, P.L.6
-
6
-
-
0035989912
-
Molecular regulation of melanocyte senescence
-
D.C. Bennett, and E.E. Medrano Molecular regulation of melanocyte senescence Pigment Cell Res 15 2002 242 250
-
(2002)
Pigment Cell Res
, vol.15
, pp. 242-250
-
-
Bennett, D.C.1
Medrano, E.E.2
-
7
-
-
19644397029
-
Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling
-
K.V. Bhatt, L.S. Spofford, G. Aram, M. McMullen, K. Pumiglia, and A.E. Aplin Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling Oncogene 24 2005 3459 3471
-
(2005)
Oncogene
, vol.24
, pp. 3459-3471
-
-
Bhatt, K.V.1
Spofford, L.S.2
Aram, G.3
McMullen, M.4
Pumiglia, K.5
Aplin, A.E.6
-
8
-
-
0036894746
-
BRAF and RAS mutations in human lung cancer and melanoma
-
M.S. Brose, P. Volpe, M. Feldman, M. Kumar, I. Rishi, and R. Gerrero BRAF and RAS mutations in human lung cancer and melanoma Cancer Res 62 2002 6997 7000
-
(2002)
Cancer Res
, vol.62
, pp. 6997-7000
-
-
Brose, M.S.1
Volpe, P.2
Feldman, M.3
Kumar, M.4
Rishi, I.5
Gerrero, R.6
-
9
-
-
3542996265
-
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
-
S. Burdette-Radoux, R.G. Tozer, R.C. Lohmann, I. Quirt, D.S. Ernst, and W. Walsh Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma Invest New Drugs 22 2004 315 322
-
(2004)
Invest New Drugs
, vol.22
, pp. 315-322
-
-
Burdette-Radoux, S.1
Tozer, R.G.2
Lohmann, R.C.3
Quirt, I.4
Ernst, D.S.5
Walsh, W.6
-
10
-
-
54549108740
-
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
-
Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 2008 1061 1068
-
(2008)
Nature
, vol.455
, pp. 1061-1068
-
-
-
11
-
-
84877028141
-
Comprehensive molecular portraits of human breast tumours
-
Cancer Genome Atlas Research Network Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
-
(2012)
Nature
, vol.490
, pp. 61-70
-
-
-
12
-
-
84866894408
-
Comprehensive genomic characterization of squamous cell lung cancers
-
Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers Nature 489 2012 519 525
-
(2012)
Nature
, vol.489
, pp. 519-525
-
-
-
13
-
-
84905029258
-
Comprehensive molecular profiling of lung adenocarcinoma
-
Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma Nature 511 2014 543 550
-
(2014)
Nature
, vol.511
, pp. 543-550
-
-
-
14
-
-
84880480387
-
Cyclins and cell cycle control in cancer and disease
-
M.C. Casimiro, M. Crosariol, E. Loro, Z. Li, and R.G. Pestell Cyclins and cell cycle control in cancer and disease Genes Cancer 3 2012 649 657
-
(2012)
Genes Cancer
, vol.3
, pp. 649-657
-
-
Casimiro, M.C.1
Crosariol, M.2
Loro, E.3
Li, Z.4
Pestell, R.G.5
-
15
-
-
0035282334
-
Mammalian MAP kinase signalling cascades
-
L. Chang, and M. Karin Mammalian MAP kinase signalling cascades Nature 410 2001 37 40
-
(2001)
Nature
, vol.410
, pp. 37-40
-
-
Chang, L.1
Karin, M.2
-
16
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
Haanen, J.B.4
Ascierto, P.5
Larkin, J.6
-
17
-
-
84925881649
-
BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
-
[Epub ahead of print]
-
C. Chiappetta, I. Proietti, V. Soccodato, C. Puggioni, R. Zaralli, and L. Pacini BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma Appl Immunohistochem Mol Morphol 2014 [Epub ahead of print]
-
(2014)
Appl Immunohistochem Mol Morphol
-
-
Chiappetta, C.1
Proietti, I.2
Soccodato, V.3
Puggioni, C.4
Zaralli, R.5
Pacini, L.6
-
18
-
-
0031710479
-
The INK4a/ARF tumor suppressor: One gene-two products-two pathways
-
L. Chin, J. Pomerantz, and R.A. DePinho The INK4a/ARF tumor suppressor: One gene-two products-two pathways Trends Biochem Sci 23 1998 291 296
-
(1998)
Trends Biochem Sci
, vol.23
, pp. 291-296
-
-
Chin, L.1
Pomerantz, J.2
Depinho, R.A.3
-
19
-
-
22844445932
-
Use of human tissue to assess the oncogenic activity of melanoma-associated mutations
-
Y. Chudnovsky, A.E. Adams, P.B. Robbins, Q. Lin, and P.A. Khavari Use of human tissue to assess the oncogenic activity of melanoma-associated mutations Nat Genet 37 2005 745 749
-
(2005)
Nat Genet
, vol.37
, pp. 745-749
-
-
Chudnovsky, Y.1
Adams, A.E.2
Robbins, P.B.3
Lin, Q.4
Khavari, P.A.5
-
20
-
-
85047691154
-
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
-
R. Ciampi, J.A. Knauf, R. Kerler, M. Gandhi, Z. Zhu, and M.N. Nikiforova Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer J Clin Invest 115 2005 94 101
-
(2005)
J Clin Invest
, vol.115
, pp. 94-101
-
-
Ciampi, R.1
Knauf, J.A.2
Kerler, R.3
Gandhi, M.4
Zhu, Z.5
Nikiforova, M.N.6
-
21
-
-
84861863158
-
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
-
R.B. Corcoran, H. Ebi, A.B. Turke, E.M. Coffee, M. Nishino, and A.P. Cogdill EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib Cancer Discov 2 2012 227 235
-
(2012)
Cancer Discov
, vol.2
, pp. 227-235
-
-
Corcoran, R.B.1
Ebi, H.2
Turke, A.B.3
Coffee, E.M.4
Nishino, M.5
Cogdill, A.P.6
-
22
-
-
84883644630
-
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma
-
R.B. Corcoran, S.M. Rothenberg, A.N. Hata, A.C. Faber, A. Piris, and R.M. Nazarian TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma Sci Transl Med 5 2013 196ra198
-
(2013)
Sci Transl Med
, vol.5
, pp. 196ra198
-
-
Corcoran, R.B.1
Rothenberg, S.M.2
Hata, A.N.3
Faber, A.C.4
Piris, A.5
Nazarian, R.M.6
-
23
-
-
27844567142
-
Distinct sets of genetic alterations in melanoma
-
J.A. Curtin, J. Fridlyand, T. Kageshita, H.N. Patel, K.J. Busam, and H. Kutzner Distinct sets of genetic alterations in melanoma N Engl J Med 353 2005 2135 2147
-
(2005)
N Engl J Med
, vol.353
, pp. 2135-2147
-
-
Curtin, J.A.1
Fridlyand, J.2
Kageshita, T.3
Patel, H.N.4
Busam, K.J.5
Kutzner, H.6
-
24
-
-
84873728334
-
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
-
M. Das Thakur, F. Salangsang, A.S. Landman, W.R. Sellers, N.K. Pryer, and M.P. Levesque Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance Nature 494 2013 251 255
-
(2013)
Nature
, vol.494
, pp. 251-255
-
-
Das Thakur, M.1
Salangsang, F.2
Landman, A.S.3
Sellers, W.R.4
Pryer, N.K.5
Levesque, M.P.6
-
25
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
-
(2002)
Nature
, vol.417
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
Stephens, P.4
Edkins, S.5
Clegg, S.6
-
26
-
-
63249105225
-
Oncogenic Braf induces melanocyte senescence and melanoma in mice
-
N. Dhomen, J.S. Reis-Filho, S. da Rocha Dias, R. Hayward, K. Savage, and V. Delmas Oncogenic Braf induces melanocyte senescence and melanoma in mice Cancer Cell 15 2009 294 303
-
(2009)
Cancer Cell
, vol.15
, pp. 294-303
-
-
Dhomen, N.1
Reis-Filho, J.S.2
Da Rocha Dias, S.3
Hayward, R.4
Savage, K.5
Delmas, V.6
-
27
-
-
84903843882
-
Molecular pathways: CDK4 inhibitors for cancer therapy
-
M.A. Dickson Molecular pathways: CDK4 inhibitors for cancer therapy Clin Cancer Res 20 2014 3379 3383
-
(2014)
Clin Cancer Res
, vol.20
, pp. 3379-3383
-
-
Dickson, M.A.1
-
28
-
-
84883062033
-
Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia
-
S. Dietrich, J. Hullein, M. Hundemer, N. Lehners, A. Jethwa, and D. Capper Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia J Clin Oncol 31 2013 e300 e303
-
(2013)
J Clin Oncol
, vol.31
, pp. e300-e303
-
-
Dietrich, S.1
Hullein, J.2
Hundemer, M.3
Lehners, N.4
Jethwa, A.5
Capper, D.6
-
29
-
-
0042743826
-
BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma
-
J. Dong, R.G. Phelps, R. Qiao, S. Yao, O. Benard, and Z. Ronai BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma Cancer Res 63 2003 3883 3885
-
(2003)
Cancer Res
, vol.63
, pp. 3883-3885
-
-
Dong, J.1
Phelps, R.G.2
Qiao, R.3
Yao, S.4
Benard, O.5
Ronai, Z.6
-
30
-
-
33748325763
-
Sorafenib in advanced melanoma: A Phase II randomised discontinuation trial analysis
-
T. Eisen, T. Ahmad, K.T. Flaherty, M. Gore, S. Kaye, and R. Marais Sorafenib in advanced melanoma: A Phase II randomised discontinuation trial analysis Br J Cancer 95 2006 581 586
-
(2006)
Br J Cancer
, vol.95
, pp. 581-586
-
-
Eisen, T.1
Ahmad, T.2
Flaherty, K.T.3
Gore, M.4
Kaye, S.5
Marais, R.6
-
31
-
-
84920841992
-
BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer
-
[Epub ahead of print]
-
G.S. Falchook, M. Millward, D.S. Hong, A. Naing, S. Piha-Paul, and S.G. Waguespack BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer Thyroid 2014 10.1089/thy.2014.0123 [Epub ahead of print]
-
(2014)
Thyroid
-
-
Falchook, G.S.1
Millward, M.2
Hong, D.S.3
Naing, A.4
Piha-Paul, S.5
Waguespack, S.G.6
-
32
-
-
0028152992
-
Induction of cyclin D1 overexpression by activated ras
-
J. Filmus, A.I. Robles, W. Shi, M.J. Wong, L.L. Colombo, and C.J. Conti Induction of cyclin D1 overexpression by activated ras Oncogene 9 1994 3627 3633
-
(1994)
Oncogene
, vol.9
, pp. 3627-3633
-
-
Filmus, J.1
Robles, A.I.2
Shi, W.3
Wong, M.J.4
Colombo, L.L.5
Conti, C.J.6
-
33
-
-
76049104235
-
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
-
R.S. Finn, J. Dering, D. Conklin, O. Kalous, D.J. Cohen, and A.J. Desai PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro Breast Cancer Res 11 2009 R77
-
(2009)
Breast Cancer Res
, vol.11
, pp. R77
-
-
Finn, R.S.1
Dering, J.2
Conklin, D.3
Kalous, O.4
Cohen, D.J.5
Desai, A.J.6
-
34
-
-
84855983664
-
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer
-
K.T. Flaherty, P.M. Lorusso, A. Demichele, V.G. Abramson, R. Courtney, and S.S. Randolph Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer Clin Cancer Res 18 2012 568 576
-
(2012)
Clin Cancer Res
, vol.18
, pp. 568-576
-
-
Flaherty, K.T.1
Lorusso, P.M.2
Demichele, A.3
Abramson, V.G.4
Courtney, R.5
Randolph, S.S.6
-
35
-
-
77956030786
-
Inhibition of mutated, activated BRAF in metastatic melanoma
-
K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, and J.A. Sosman Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
-
(2010)
N Engl J Med
, vol.363
, pp. 809-819
-
-
Flaherty, K.T.1
Puzanov, I.2
Kim, K.B.3
Ribas, A.4
McArthur, G.A.5
Sosman, J.A.6
-
36
-
-
84874225181
-
Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling
-
A.K. Freeman, D.A. Ritt, and D.K. Morrison Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling Mol Cell 49 2013 751 758
-
(2013)
Mol Cell
, vol.49
, pp. 751-758
-
-
Freeman, A.K.1
Ritt, D.A.2
Morrison, D.K.3
-
37
-
-
9444228344
-
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
-
D.W. Fry, P.J. Harvey, P.R. Keller, W.L. Elliott, M. Meade, and E. Trachet Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts Mol Cancer Ther 3 2004 1427 1438
-
(2004)
Mol Cancer Ther
, vol.3
, pp. 1427-1438
-
-
Fry, D.W.1
Harvey, P.J.2
Keller, P.R.3
Elliott, W.L.4
Meade, M.5
Trachet, E.6
-
38
-
-
0142135475
-
BRAF mutations in papillary carcinomas of the thyroid
-
T. Fukushima, S. Suzuki, M. Mashiko, T. Ohtake, Y. Endo, and Y. Takebayashi BRAF mutations in papillary carcinomas of the thyroid Oncogene 22 2003 6455 6457
-
(2003)
Oncogene
, vol.22
, pp. 6455-6457
-
-
Fukushima, T.1
Suzuki, S.2
Mashiko, M.3
Ohtake, T.4
Endo, Y.5
Takebayashi, Y.6
-
39
-
-
84875740314
-
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal
-
(pl1)
-
J. Gao, B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, and S.O. Sumer Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal Sci Signal 6 2013 (pl1)
-
(2013)
Sci Signal
, vol.6
-
-
Gao, J.1
Aksoy, B.A.2
Dogrusoz, U.3
Dresdner, G.4
Gross, B.5
Sumer, S.O.6
-
40
-
-
5444227865
-
Guilty as charged: B-RAF is a human oncogene
-
M.J. Garnett, and R. Marais Guilty as charged: B-RAF is a human oncogene Cancer Cell 6 2004 313 319
-
(2004)
Cancer Cell
, vol.6
, pp. 313-319
-
-
Garnett, M.J.1
Marais, R.2
-
41
-
-
77953500573
-
Somatic alterations in the melanoma genome: A high-resolution array-based comparative genomic hybridization study
-
A. Gast, D. Scherer, B. Chen, S. Bloethner, S. Melchert, and A. Sucker Somatic alterations in the melanoma genome: A high-resolution array-based comparative genomic hybridization study Genes Chromosomes Cancer 49 2010 733 745
-
(2010)
Genes Chromosomes Cancer
, vol.49
, pp. 733-745
-
-
Gast, A.1
Scherer, D.2
Chen, B.3
Bloethner, S.4
Melchert, S.5
Sucker, A.6
-
42
-
-
84930696140
-
Preclinical characterization of the CDK4/6 inhibitor LY2835219: In-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
-
L.M. Gelbert, S. Cai, X. Lin, C. Sanchez-Martinez, M. Del Prado, and M.J. Lallena Preclinical characterization of the CDK4/6 inhibitor LY2835219: In-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine Invest New Drugs 32 2014 825 837
-
(2014)
Invest New Drugs
, vol.32
, pp. 825-837
-
-
Gelbert, L.M.1
Cai, S.2
Lin, X.3
Sanchez-Martinez, C.4
Del Prado, M.5
Lallena, M.J.6
-
43
-
-
84863922124
-
Comprehensive molecular characterization of human colon and rectal cancer
-
Cancer Genome Atlas Network
-
Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer Nature 487 2012 330 337
-
(2012)
Nature
, vol.487
, pp. 330-337
-
-
-
44
-
-
84873907015
-
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma
-
M.R. Girotti, M. Pedersen, B. Sanchez-Laorden, A. Viros, S. Turajlic, and D. Niculescu-Duvaz Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma Cancer Discov 3 2013 158 167
-
(2013)
Cancer Discov
, vol.3
, pp. 158-167
-
-
Girotti, M.R.1
Pedersen, M.2
Sanchez-Laorden, B.3
Viros, A.4
Turajlic, S.5
Niculescu-Duvaz, D.6
-
45
-
-
67349212438
-
Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice
-
V.K. Goel, N. Ibrahim, G. Jiang, M. Singhal, S. Fee, and T. Flotte Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice Oncogene 28 2009 2289 2298
-
(2009)
Oncogene
, vol.28
, pp. 2289-2298
-
-
Goel, V.K.1
Ibrahim, N.2
Jiang, G.3
Singhal, M.4
Fee, S.5
Flotte, T.6
-
46
-
-
0029119740
-
Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)
-
X. Grana, and E.P. Reddy Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs) Oncogene 11 1995 211 219
-
(1995)
Oncogene
, vol.11
, pp. 211-219
-
-
Grana, X.1
Reddy, E.P.2
-
47
-
-
84874518093
-
Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma
-
W.O. Greaves, S. Verma, K.P. Patel, M.A. Davies, B.A. Barkoh, and J.M. Galbincea Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma J Mol Diagn 15 2013 220 226
-
(2013)
J Mol Diagn
, vol.15
, pp. 220-226
-
-
Greaves, W.O.1
Verma, S.2
Patel, K.P.3
Davies, M.A.4
Barkoh, B.A.5
Galbincea, J.M.6
-
48
-
-
33645510413
-
Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice
-
E. Hacker, H.K. Muller, N. Irwin, B. Gabrielli, D. Lincoln, and S. Pavey Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice Cancer Res 66 2006 2946 2952
-
(2006)
Cancer Res
, vol.66
, pp. 2946-2952
-
-
Hacker, E.1
Muller, H.K.2
Irwin, N.3
Gabrielli, B.4
Lincoln, D.5
Pavey, S.6
-
49
-
-
0034614637
-
The hallmarks of cancer
-
D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
-
(2000)
Cell
, vol.100
, pp. 57-70
-
-
Hanahan, D.1
Weinberg, R.A.2
-
50
-
-
77949685981
-
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
-
G. Hatzivassiliou, K. Song, I. Yen, B.J. Brandhuber, D.J. Anderson, and R. Alvarado RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 464 2010 431 435
-
(2010)
Nature
, vol.464
, pp. 431-435
-
-
Hatzivassiliou, G.1
Song, K.2
Yen, I.3
Brandhuber, B.J.4
Anderson, D.J.5
Alvarado, R.6
-
51
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
-
A. Hauschild, J.J. Grob, L.V. Demidov, T. Jouary, R. Gutzmer, and M. Millward Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
-
(2012)
Lancet
, vol.380
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
Jouary, T.4
Gutzmer, R.5
Millward, M.6
-
52
-
-
0038795172
-
Genetics of melanoma predisposition
-
N.K. Hayward Genetics of melanoma predisposition Oncogene 22 2003 3053 3062
-
(2003)
Oncogene
, vol.22
, pp. 3053-3062
-
-
Hayward, N.K.1
-
53
-
-
74849109743
-
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
-
S.J. Heidorn, C. Milagre, S. Whittaker, A. Nourry, I. Niculescu-Duvas, and N. Dhomen Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 140 2010 209 221
-
(2010)
Cell
, vol.140
, pp. 209-221
-
-
Heidorn, S.J.1
Milagre, C.2
Whittaker, S.3
Nourry, A.4
Niculescu-Duvas, I.5
Dhomen, N.6
-
55
-
-
84864258996
-
A landscape of driver mutations in melanoma
-
E. Hodis, I.R. Watson, G.V. Kryukov, S.T. Arold, M. Imielinski, and J.P. Theurillat A landscape of driver mutations in melanoma Cell 150 2012 251 263
-
(2012)
Cell
, vol.150
, pp. 251-263
-
-
Hodis, E.1
Watson, I.R.2
Kryukov, G.V.3
Arold, S.T.4
Imielinski, M.5
Theurillat, J.P.6
-
56
-
-
84877825519
-
RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation
-
M. Holderfield, H. Merritt, J. Chan, M. Wallroth, L. Tandeske, and H. Zhai RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation Cancer Cell 23 2013 594 602
-
(2013)
Cancer Cell
, vol.23
, pp. 594-602
-
-
Holderfield, M.1
Merritt, H.2
Chan, J.3
Wallroth, M.4
Tandeske, L.5
Zhai, H.6
-
57
-
-
84890621086
-
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition
-
K.E. Hutchinson, D. Lipson, P.J. Stephens, G. Otto, B.D. Lehmann, and P.L. Lyle BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition Clin Cancer Res 19 2013 6696 6702
-
(2013)
Clin Cancer Res
, vol.19
, pp. 6696-6702
-
-
Hutchinson, K.E.1
Lipson, D.2
Stephens, P.J.3
Otto, G.4
Lehmann, B.D.5
Lyle, P.L.6
-
58
-
-
10744232660
-
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors
-
T. Ikenoue, Y. Hikiba, F. Kanai, Y. Tanaka, J. Imamura, and T. Imamura Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors Cancer Res 63 2003 8132 8137
-
(2003)
Cancer Res
, vol.63
, pp. 8132-8137
-
-
Ikenoue, T.1
Hikiba, Y.2
Kanai, F.3
Tanaka, Y.4
Imamura, J.5
Imamura, T.6
-
59
-
-
84866410479
-
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing
-
M. Imielinski, A.H. Berger, P.S. Hammerman, B. Hernandez, T.J. Pugh, and E. Hodis Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing Cell 150 2012 1107 1120
-
(2012)
Cell
, vol.150
, pp. 1107-1120
-
-
Imielinski, M.1
Berger, A.H.2
Hammerman, P.S.3
Hernandez, B.4
Pugh, T.J.5
Hodis, E.6
-
60
-
-
78650309875
-
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
-
C.M. Johannessen, J.S. Boehm, S.Y. Kim, S.R. Thomas, L. Wardwell, and L.A. Johnson COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 2010 968 972
-
(2010)
Nature
, vol.468
, pp. 968-972
-
-
Johannessen, C.M.1
Boehm, J.S.2
Kim, S.Y.3
Thomas, S.R.4
Wardwell, L.5
Johnson, L.A.6
-
61
-
-
0035150990
-
Growth-factor-dependent mitogenesis requires two distinct phases of signalling
-
S.M. Jones, and A. Kazlauskas Growth-factor-dependent mitogenesis requires two distinct phases of signalling Nat Cell Biol 3 2001 165 172
-
(2001)
Nat Cell Biol
, vol.3
, pp. 165-172
-
-
Jones, S.M.1
Kazlauskas, A.2
-
62
-
-
55349107544
-
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas
-
D.T. Jones, S. Kocialkowski, L. Liu, D.M. Pearson, L.M. Backlund, and K. Ichimura Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas Cancer Res 68 2008 8673 8677
-
(2008)
Cancer Res
, vol.68
, pp. 8673-8677
-
-
Jones, D.T.1
Kocialkowski, S.2
Liu, L.3
Pearson, D.M.4
Backlund, L.M.5
Ichimura, K.6
-
63
-
-
77957089182
-
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
-
E.W. Joseph, C.A. Pratilas, P.I. Poulikakos, M. Tadi, W. Wang, and B.S. Taylor The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Proc Natl Acad Sci U S A 107 2010 14903 14908
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 14903-14908
-
-
Joseph, E.W.1
Pratilas, C.A.2
Poulikakos, P.I.3
Tadi, M.4
Wang, W.5
Taylor, B.S.6
-
64
-
-
0037418002
-
Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model
-
K. Kannan, N.E. Sharpless, J. Xu, R.C. O'Hagan, M. Bosenberg, and L. Chin Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model Proc Natl Acad Sci U S A 100 2003 1221 1225
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 1221-1225
-
-
Kannan, K.1
Sharpless, N.E.2
Xu, J.3
O'Hagan, R.C.4
Bosenberg, M.5
Chin, L.6
-
65
-
-
9244251125
-
Cell-cycle checkpoints and cancer
-
M.B. Kastan, and J. Bartek Cell-cycle checkpoints and cancer Nature 432 2004 316 323
-
(2004)
Nature
, vol.432
, pp. 316-323
-
-
Kastan, M.B.1
Bartek, J.2
-
66
-
-
84874777853
-
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
-
K.B. Kim, R. Kefford, A.C. Pavlick, J.R. Infante, A. Ribas, and J.A. Sosman Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor J Clin Oncol 31 2013 482 489
-
(2013)
J Clin Oncol
, vol.31
, pp. 482-489
-
-
Kim, K.B.1
Kefford, R.2
Pavlick, A.C.3
Infante, J.R.4
Ribas, A.5
Sosman, J.A.6
-
67
-
-
84877853153
-
Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma
-
Y.S. Kim, J.S. Kim, J.S. Bae, and W.C. Park Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma World J Surg Oncol 11 2013 99
-
(2013)
World J Surg Oncol
, vol.11
, pp. 99
-
-
Kim, Y.S.1
Kim, J.S.2
Bae, J.S.3
Park, W.C.4
-
68
-
-
59349108429
-
Transcriptional regulation of the cyclin D1 gene at a glance
-
E.A. Klein, and R.K. Assoian Transcriptional regulation of the cyclin D1 gene at a glance J Cell Sci 121 2008 3853 3857
-
(2008)
J Cell Sci
, vol.121
, pp. 3853-3857
-
-
Klein, E.A.1
Assoian, R.K.2
-
69
-
-
50149084928
-
Tailoring to RB: Tumour suppressor status and therapeutic response
-
E.S. Knudsen, and K.E. Knudsen Tailoring to RB: Tumour suppressor status and therapeutic response Nat Rev Cancer 8 2008 714 724
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 714-724
-
-
Knudsen, E.S.1
Knudsen, K.E.2
-
70
-
-
79952710710
-
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer
-
G.E. Konecny, B. Winterhoff, T. Kolarova, J. Qi, K. Manivong, and J. Dering Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer Clin Cancer Res 17 2011 1591 1602
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1591-1602
-
-
Konecny, G.E.1
Winterhoff, B.2
Kolarova, T.3
Qi, J.4
Manivong, K.5
Dering, J.6
-
71
-
-
84870289371
-
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
-
L.N. Kwong, J.C. Costello, H. Liu, S. Jiang, T.L. Helms, and A.E. Langsdorf Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma Nat Med 18 2012 1503 1510
-
(2012)
Nat Med
, vol.18
, pp. 1503-1510
-
-
Kwong, L.N.1
Costello, J.C.2
Liu, H.3
Jiang, S.4
Helms, T.L.5
Langsdorf, A.E.6
-
72
-
-
67650073265
-
Cell cycle kinases as therapeutic targets for cancer
-
S. Lapenna, and A. Giordano Cell cycle kinases as therapeutic targets for cancer Nat Rev Drug Discov 8 2009 547 566
-
(2009)
Nat Rev Drug Discov
, vol.8
, pp. 547-566
-
-
Lapenna, S.1
Giordano, A.2
-
73
-
-
84862697903
-
A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation
-
N.V. Lee, M.E. Lira, A. Pavlicek, J. Ye, D. Buckman, and S. Bagrodia A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation PLoS One 7 2012 e39653
-
(2012)
PLoS One
, vol.7
, pp. e39653
-
-
Lee, N.V.1
Lira, M.E.2
Pavlicek, A.3
Ye, J.4
Buckman, D.5
Bagrodia, S.6
-
74
-
-
84861210266
-
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
-
J.P. Leonard, A.S. LaCasce, M.R. Smith, A. Noy, L.R. Chirieac, and S.J. Rodig Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma Blood 119 2012 4597 4607
-
(2012)
Blood
, vol.119
, pp. 4597-4607
-
-
Leonard, J.P.1
Lacasce, A.S.2
Smith, M.R.3
Noy, A.4
Chirieac, L.R.5
Rodig, S.J.6
-
75
-
-
84887478023
-
Tumor adaptation and resistance to RAF inhibitors
-
P. Lito, N. Rosen, and D.B. Solit Tumor adaptation and resistance to RAF inhibitors Nat Med 19 2013 1401 1409
-
(2013)
Nat Med
, vol.19
, pp. 1401-1409
-
-
Lito, P.1
Rosen, N.2
Solit, D.B.3
-
76
-
-
84868120907
-
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial
-
G.V. Long, U. Trefzer, M.A. Davies, R.F. Kefford, P.A. Ascierto, and P.B. Chapman Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial Lancet Oncol 13 2012 1087 1095
-
(2012)
Lancet Oncol
, vol.13
, pp. 1087-1095
-
-
Long, G.V.1
Trefzer, U.2
Davies, M.A.3
Kefford, R.F.4
Ascierto, P.A.5
Chapman, P.B.6
-
77
-
-
77954152739
-
Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors
-
Z. Lu, and T. Hunter Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors Cell Cycle 9 2010 2342 2352
-
(2010)
Cell Cycle
, vol.9
, pp. 2342-2352
-
-
Lu, Z.1
Hunter, T.2
-
78
-
-
0035754080
-
To cycle or not to cycle: A critical decision in cancer
-
M. Malumbres, and M. Barbacid To cycle or not to cycle: A critical decision in cancer Nat Rev Cancer 1 2001 222 231
-
(2001)
Nat Rev Cancer
, vol.1
, pp. 222-231
-
-
Malumbres, M.1
Barbacid, M.2
-
79
-
-
60749109846
-
Cell cycle, CDKs and cancer: A changing paradigm
-
M. Malumbres, and M. Barbacid Cell cycle, CDKs and cancer: A changing paradigm Nat Rev Cancer 9 2009 153 166
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 153-166
-
-
Malumbres, M.1
Barbacid, M.2
-
80
-
-
4444247138
-
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
-
M. Malumbres, R. Sotillo, D. Santamaria, J. Galan, A. Cerezo, and S. Ortega Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6 Cell 118 2004 493 504
-
(2004)
Cell
, vol.118
, pp. 493-504
-
-
Malumbres, M.1
Sotillo, R.2
Santamaria, D.3
Galan, J.4
Cerezo, A.5
Ortega, S.6
-
81
-
-
84857654700
-
RB: Mitotic implications of a tumour suppressor
-
A.L. Manning, and N.J. Dyson RB: Mitotic implications of a tumour suppressor Nat Rev Cancer 12 2012 220 226
-
(2012)
Nat Rev Cancer
, vol.12
, pp. 220-226
-
-
Manning, A.L.1
Dyson, N.J.2
-
82
-
-
84873360893
-
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
-
M. Mao, F. Tian, J.M. Mariadason, C.C. Tsao, R. Lemos Jr., and F. Dayyani Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents Clin Cancer Res 19 2013 657 667
-
(2013)
Clin Cancer Res
, vol.19
, pp. 657-667
-
-
Mao, M.1
Tian, F.2
Mariadason, J.M.3
Tsao, C.C.4
Lemos, Jr.R.5
Dayyani, F.6
-
83
-
-
9244239811
-
G1 cell-cycle control and cancer
-
J. Massague G1 cell-cycle control and cancer Nature 432 2004 298 306
-
(2004)
Nature
, vol.432
, pp. 298-306
-
-
Massague, J.1
-
84
-
-
23244447037
-
BRAFE600-associated senescence-like cell cycle arrest of human naevi
-
C. Michaloglou, L.C. Vredeveld, M.S. Soengas, C. Denoyelle, T. Kuilman, and C.M. van der Horst BRAFE600-associated senescence-like cell cycle arrest of human naevi Nature 436 2005 720 724
-
(2005)
Nature
, vol.436
, pp. 720-724
-
-
Michaloglou, C.1
Vredeveld, L.C.2
Soengas, M.S.3
Denoyelle, C.4
Kuilman, T.5
Van Der Horst, C.M.6
-
85
-
-
78049345763
-
Somatic p16(INK4a) loss accelerates melanomagenesis
-
K.B. Monahan, G.I. Rozenberg, J. Krishnamurthy, S.M. Johnson, W. Liu, and M.K. Bradford Somatic p16(INK4a) loss accelerates melanomagenesis Oncogene 29 2010 5809 5817
-
(2010)
Oncogene
, vol.29
, pp. 5809-5817
-
-
Monahan, K.B.1
Rozenberg, G.I.2
Krishnamurthy, J.3
Johnson, S.M.4
Liu, W.5
Bradford, M.K.6
-
86
-
-
49649118852
-
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
-
C. Montagut, S.V. Sharma, T. Shioda, U. McDermott, M. Ulman, and L.E. Ulkus Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma Cancer Res 68 2008 4853 4861
-
(2008)
Cancer Res
, vol.68
, pp. 4853-4861
-
-
Montagut, C.1
Sharma, S.V.2
Shioda, T.3
McDermott, U.4
Ulman, M.5
Ulkus, L.E.6
-
87
-
-
84877631604
-
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas
-
C. Montero-Conde, S. Ruiz-Llorente, J.M. Dominguez, J.A. Knauf, A. Viale, and E.J. Sherman Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas Cancer Discov 3 2013 520 533
-
(2013)
Cancer Discov
, vol.3
, pp. 520-533
-
-
Montero-Conde, C.1
Ruiz-Llorente, S.2
Dominguez, J.M.3
Knauf, J.A.4
Viale, A.5
Sherman, E.J.6
-
88
-
-
84908219463
-
Progression-Free Survival Remains Poor over Sequential Lines of Systemic Therapy in Patients with BRAF-Mutated Colorectal Cancer
-
V. Morris, M.J. Overman, Z.Q. Jiang, C. Garrett, S. Agarwal, and C. Eng Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer Clin Colorectal Cancer 13 2014 164 171
-
(2014)
Clin Colorectal Cancer
, vol.13
, pp. 164-171
-
-
Morris, V.1
Overman, M.J.2
Jiang, Z.Q.3
Garrett, C.4
Agarwal, S.5
Eng, C.6
-
89
-
-
79960836823
-
Cyclin D as a therapeutic target in cancer
-
E.A. Musgrove, C.E. Caldon, J. Barraclough, A. Stone, and R.L. Sutherland Cyclin D as a therapeutic target in cancer Nat Rev Cancer 11 2011 558 572
-
(2011)
Nat Rev Cancer
, vol.11
, pp. 558-572
-
-
Musgrove, E.A.1
Caldon, C.E.2
Barraclough, J.3
Stone, A.4
Sutherland, R.L.5
-
90
-
-
33646345376
-
Ubiquitin ligases: Cell-cycle control and cancer
-
K.I. Nakayama, and K. Nakayama Ubiquitin ligases: Cell-cycle control and cancer Nat Rev Cancer 6 2006 369 381
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 369-381
-
-
Nakayama, K.I.1
Nakayama, K.2
-
91
-
-
84883482902
-
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)
-
K.L. Nathanson, A.M. Martin, B. Wubbenhorst, J. Greshock, R. Letrero, and K. D'Andrea Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436) Clin Cancer Res 19 2013 4868 4878
-
(2013)
Clin Cancer Res
, vol.19
, pp. 4868-4878
-
-
Nathanson, K.L.1
Martin, A.M.2
Wubbenhorst, B.3
Greshock, J.4
Letrero, R.5
D'Andrea, K.6
-
92
-
-
78650303507
-
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
-
R. Nazarian, H. Shi, Q. Wang, X. Kong, R.C. Koya, and H. Lee Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 2010 973 977
-
(2010)
Nature
, vol.468
, pp. 973-977
-
-
Nazarian, R.1
Shi, H.2
Wang, Q.3
Kong, X.4
Koya, R.C.5
Lee, H.6
-
93
-
-
77954526989
-
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
-
N. Palanisamy, B. Ateeq, S. Kalyana-Sundaram, D. Pflueger, K. Ramnarayanan, and S. Shankar Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma Nat Med 16 2010 793 798
-
(2010)
Nat Med
, vol.16
, pp. 793-798
-
-
Palanisamy, N.1
Ateeq, B.2
Kalyana-Sundaram, S.3
Pflueger, D.4
Ramnarayanan, K.5
Shankar, S.6
-
94
-
-
79953325104
-
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression
-
K.H. Paraiso, Y. Xiang, V.W. Rebecca, E.V. Abel, Y.A. Chen, and A.C. Munko PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression Cancer Res 71 2011 2750 2760
-
(2011)
Cancer Res
, vol.71
, pp. 2750-2760
-
-
Paraiso, K.H.1
Xiang, Y.2
Rebecca, V.W.3
Abel, E.V.4
Chen, Y.A.5
Munko, A.C.6
-
95
-
-
0037228055
-
High frequency of BRAF mutations in nevi
-
P.M. Pollock, U.L. Harper, K.S. Hansen, L.M. Yudt, M. Stark, and C.M. Robbins High frequency of BRAF mutations in nevi Nat Genet 33 2003 19 20
-
(2003)
Nat Genet
, vol.33
, pp. 19-20
-
-
Pollock, P.M.1
Harper, U.L.2
Hansen, K.S.3
Yudt, L.M.4
Stark, M.5
Robbins, C.M.6
-
96
-
-
83455254767
-
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
-
P.I. Poulikakos, Y. Persaud, M. Janakiraman, X. Kong, C. Ng, and G. Moriceau RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature 480 2011 387 390
-
(2011)
Nature
, vol.480
, pp. 387-390
-
-
Poulikakos, P.I.1
Persaud, Y.2
Janakiraman, M.3
Kong, X.4
Ng, C.5
Moriceau, G.6
-
97
-
-
78651418282
-
Mutant BRAF melanomas-dependence and resistance
-
P.I. Poulikakos, and N. Rosen Mutant BRAF melanomas-dependence and resistance Cancer Cell 19 2011 11 15
-
(2011)
Cancer Cell
, vol.19
, pp. 11-15
-
-
Poulikakos, P.I.1
Rosen, N.2
-
98
-
-
77949732073
-
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
-
P.I. Poulikakos, C. Zhang, G. Bollag, K.M. Shokat, and N. Rosen RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 2010 427 430
-
(2010)
Nature
, vol.464
, pp. 427-430
-
-
Poulikakos, P.I.1
Zhang, C.2
Bollag, G.3
Shokat, K.M.4
Rosen, N.5
-
99
-
-
84863230465
-
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
-
A. Prahallad, C. Sun, S. Huang, F. Di Nicolantonio, R. Salazar, and D. Zecchin Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 2012 100 103
-
(2012)
Nature
, vol.483
, pp. 100-103
-
-
Prahallad, A.1
Sun, C.2
Huang, S.3
Di Nicolantonio, F.4
Salazar, R.5
Zecchin, D.6
-
100
-
-
77954279920
-
A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma
-
M. Puyol, A. Martin, P. Dubus, F. Mulero, P. Pizcueta, and G. Khan A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma Cancer Cell 18 2010 63 73
-
(2010)
Cancer Cell
, vol.18
, pp. 63-73
-
-
Puyol, M.1
Martin, A.2
Dubus, P.3
Mulero, F.4
Pizcueta, P.5
Khan, G.6
-
101
-
-
84888082787
-
Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma
-
J. Rader, M.R. Russell, L.S. Hart, M.S. Nakazawa, L.T. Belcastro, and D. Martinez Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma Clin Cancer Res 19 2013 6173 6182
-
(2013)
Clin Cancer Res
, vol.19
, pp. 6173-6182
-
-
Rader, J.1
Russell, M.R.2
Hart, L.S.3
Nakazawa, M.S.4
Belcastro, L.T.5
Martinez, D.6
-
102
-
-
84875186930
-
Discovery of Dabrafenib: A selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors
-
T.R. Rheault, J.C. Stellwagen, G.M. Adjabeng, K.R. Hornberger, K.G. Petrov, and A.G. Waterson Discovery of Dabrafenib: A selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors ACS Med Chem Lett 4 2013 358 362
-
(2013)
ACS Med Chem Lett
, vol.4
, pp. 358-362
-
-
Rheault, T.R.1
Stellwagen, J.C.2
Adjabeng, G.M.3
Hornberger, K.R.4
Petrov, K.G.5
Waterson, A.G.6
-
103
-
-
0036605974
-
Cyclin D1 is a candidate oncogene in cutaneous melanoma
-
E.R. Sauter, U.C. Yeo, A. von Stemm, W. Zhu, S. Litwin, and D.S. Tichansky Cyclin D1 is a candidate oncogene in cutaneous melanoma Cancer Res 62 2002 3200 3206
-
(2002)
Cancer Res
, vol.62
, pp. 3200-3206
-
-
Sauter, E.R.1
Yeo, U.C.2
Von Stemm, A.3
Zhu, W.4
Litwin, S.5
Tichansky, D.S.6
-
104
-
-
79958149971
-
Phase i study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
-
G.K. Schwartz, P.M. LoRusso, M.A. Dickson, S.S. Randolph, M.N. Shaik, and K.D. Wilner Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1) Br J Cancer 104 2011 1862 1868
-
(2011)
Br J Cancer
, vol.104
, pp. 1862-1868
-
-
Schwartz, G.K.1
Lorusso, P.M.2
Dickson, M.A.3
Randolph, S.S.4
Shaik, M.N.5
Wilner, K.D.6
-
105
-
-
33745018419
-
Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma
-
M. Sensi, G. Nicolini, C. Petti, I. Bersani, F. Lozupone, and A. Molla Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma Oncogene 25 2006 3357 3364
-
(2006)
Oncogene
, vol.25
, pp. 3357-3364
-
-
Sensi, M.1
Nicolini, G.2
Petti, C.3
Bersani, I.4
Lozupone, F.5
Molla, A.6
-
106
-
-
0029993450
-
Role of the INK4a locus in tumor suppression and cell mortality
-
M. Serrano, H. Lee, L. Chin, C. Cordon-Cardo, D. Beach, and R.A. DePinho Role of the INK4a locus in tumor suppression and cell mortality Cell 85 1996 27 37
-
(1996)
Cell
, vol.85
, pp. 27-37
-
-
Serrano, M.1
Lee, H.2
Chin, L.3
Cordon-Cardo, C.4
Beach, D.5
Depinho, R.A.6
-
107
-
-
84891011530
-
A first-in-human phase i study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer
-
G. Shapiro, L.S. Rosen, A.W. Tolcher, J.W. Goldman, L. Gandhi, and K.P. Papadopoulos A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer J Clin Oncol 31 2013
-
(2013)
J Clin Oncol
, vol.31
-
-
Shapiro, G.1
Rosen, L.S.2
Tolcher, A.W.3
Goldman, J.W.4
Gandhi, L.5
Papadopoulos, K.P.6
-
108
-
-
84925624987
-
Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991
-
K.E. Sheppard, A. Foo, R. Young, K. Waldeck, R. Pearson, and G. McArthur Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991 Cancer Res 73 2013
-
(2013)
Cancer Res
, vol.73
-
-
Sheppard, K.E.1
Foo, A.2
Young, R.3
Waldeck, K.4
Pearson, R.5
McArthur, G.6
-
109
-
-
0029330474
-
Mammalian G1 cyclins and cell cycle progression
-
C.J. Sherr Mammalian G1 cyclins and cell cycle progression Proc Assoc Am Physicians 107 1995 181 186
-
(1995)
Proc Assoc Am Physicians
, vol.107
, pp. 181-186
-
-
Sherr, C.J.1
-
110
-
-
8644219655
-
Living with or without cyclins and cyclin-dependent kinases
-
C.J. Sherr, and J.M. Roberts Living with or without cyclins and cyclin-dependent kinases Genes Dev 18 2004 2699 2711
-
(2004)
Genes Dev
, vol.18
, pp. 2699-2711
-
-
Sherr, C.J.1
Roberts, J.M.2
-
111
-
-
84891898344
-
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
-
H. Shi, W. Hugo, X. Kong, A. Hong, R.C. Koya, and G. Moriceau Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy Cancer Discov 4 2014 80 93
-
(2014)
Cancer Discov
, vol.4
, pp. 80-93
-
-
Shi, H.1
Hugo, W.2
Kong, X.3
Hong, A.4
Koya, R.C.5
Moriceau, G.6
-
112
-
-
84859183431
-
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
-
H. Shi, G. Moriceau, X. Kong, M.K. Lee, H. Lee, and R.C. Koya Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance Nat Commun 3 2012 724
-
(2012)
Nat Commun
, vol.3
, pp. 724
-
-
Shi, H.1
Moriceau, G.2
Kong, X.3
Lee, M.K.4
Lee, H.5
Koya, R.C.6
-
113
-
-
33745075558
-
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases
-
K.S. Smalley, N.K. Haass, P.A. Brafford, M. Lioni, K.T. Flaherty, and M. Herlyn Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases Mol Cancer Ther 5 2006 1136 1144
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 1136-1144
-
-
Smalley, K.S.1
Haass, N.K.2
Brafford, P.A.3
Lioni, M.4
Flaherty, K.T.5
Herlyn, M.6
-
114
-
-
54049158957
-
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
-
K.S. Smalley, M. Lioni, M. Dalla Palma, M. Xiao, B. Desai, and S. Egyhazi Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas Mol Cancer Ther 7 2008 2876 2883
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 2876-2883
-
-
Smalley, K.S.1
Lioni, M.2
Dalla Palma, M.3
Xiao, M.4
Desai, B.5
Egyhazi, S.6
-
115
-
-
84912110744
-
A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity
-
J.A. Sosman, M. Kittaneh, M.P.J.K. Lolkema, M.A. Postow, G. Schwartz, and C. Franklin A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity ASCO Meeting Abstracts 32 2014 9009
-
(2014)
ASCO Meeting Abstracts
, vol.32
, pp. 9009
-
-
Sosman, J.A.1
Kittaneh, M.2
Lolkema, M.P.J.K.3
Postow, M.A.4
Schwartz, G.5
Franklin, C.6
-
116
-
-
84922373207
-
The landscape of kinase fusions in cancer
-
N. Stransky, E. Cerami, S. Schalm, J.L. Kim, and C. Lengauer The landscape of kinase fusions in cancer Nat Commun 5 2014 4846
-
(2014)
Nat Commun
, vol.5
, pp. 4846
-
-
Stransky, N.1
Cerami, E.2
Schalm, S.3
Kim, J.L.4
Lengauer, C.5
-
117
-
-
84864285794
-
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
-
R. Straussman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z.R. Qian, and J. Du Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 487 2012 500 504
-
(2012)
Nature
, vol.487
, pp. 500-504
-
-
Straussman, R.1
Morikawa, T.2
Shee, K.3
Barzily-Rokni, M.4
Qian, Z.R.5
Du, J.6
-
118
-
-
84863115580
-
Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
-
F. Su, W.D. Bradley, Q. Wang, H. Yang, L. Xu, and B. Higgins Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation Cancer Res 72 2012 969 978
-
(2012)
Cancer Res
, vol.72
, pp. 969-978
-
-
Su, F.1
Bradley, W.D.2
Wang, Q.3
Yang, H.4
Xu, L.5
Higgins, B.6
-
119
-
-
84875675990
-
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia
-
E. Tiacci, G. Schiavoni, M.P. Martelli, E. Boveri, R. Pacini, and A. Tabarrini Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia Haematologica 98 2013 635 639
-
(2013)
Haematologica
, vol.98
, pp. 635-639
-
-
Tiacci, E.1
Schiavoni, G.2
Martelli, M.P.3
Boveri, E.4
Pacini, R.5
Tabarrini, A.6
-
120
-
-
2442675270
-
ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest
-
D.E. Todd, R.M. Densham, S.A. Molton, K. Balmanno, C. Newson, and C.R. Weston ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest Oncogene 23 2004 3284 3295
-
(2004)
Oncogene
, vol.23
, pp. 3284-3295
-
-
Todd, D.E.1
Densham, R.M.2
Molton, S.A.3
Balmanno, K.4
Newson, C.5
Weston, C.R.6
-
121
-
-
84891894051
-
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma
-
E.M. Van Allen, N. Wagle, A. Sucker, D.J. Treacy, C.M. Johannessen, and E.M. Goetz The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma Cancer Discov 4 2014 94 109
-
(2014)
Cancer Discov
, vol.4
, pp. 94-109
-
-
Van Allen, E.M.1
Wagle, N.2
Sucker, A.3
Treacy, D.J.4
Johannessen, C.M.5
Goetz, E.M.6
-
122
-
-
78650008177
-
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
-
J. Villanueva, A. Vultur, J.T. Lee, R. Somasundaram, M. Fukunaga-Kalabis, and A.K. Cipolla Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 2010 683 695
-
(2010)
Cancer Cell
, vol.18
, pp. 683-695
-
-
Villanueva, J.1
Vultur, A.2
Lee, J.T.3
Somasundaram, R.4
Fukunaga-Kalabis, M.5
Cipolla, A.K.6
-
123
-
-
80051625929
-
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
-
N. Wagle, C. Emery, M.F. Berger, M.J. Davis, A. Sawyer, and P. Pochanard Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling J Clin Oncol 29 2011 3085 3096
-
(2011)
J Clin Oncol
, vol.29
, pp. 3085-3096
-
-
Wagle, N.1
Emery, C.2
Berger, M.F.3
Davis, M.J.4
Sawyer, A.5
Pochanard, P.6
-
124
-
-
0031980540
-
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets
-
G.J. Walker, J.F. Flores, J.M. Glendening, A.H. Lin, I.D. Markl, and J.W. Fountain Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets Genes Chromosomes Cancer 22 1998 157 163
-
(1998)
Genes Chromosomes Cancer
, vol.22
, pp. 157-163
-
-
Walker, G.J.1
Flores, J.F.2
Glendening, J.M.3
Lin, A.H.4
Markl, I.D.5
Fountain, J.W.6
-
125
-
-
12144289677
-
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
-
P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, and V.M. Good Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
-
(2004)
Cell
, vol.116
, pp. 855-867
-
-
Wan, P.T.1
Garnett, M.J.2
Roe, S.M.3
Lee, S.4
Niculescu-Duvaz, D.5
Good, V.M.6
-
126
-
-
34548838818
-
Pharmacologic inhibition of CDK4/6: Mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia
-
L. Wang, J. Wang, B.W. Blaser, A.M. Duchemin, D.F. Kusewitt, and T. Liu Pharmacologic inhibition of CDK4/6: Mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia Blood 110 2007 2075 2082
-
(2007)
Blood
, vol.110
, pp. 2075-2082
-
-
Wang, L.1
Wang, J.2
Blaser, B.W.3
Duchemin, A.M.4
Kusewitt, D.F.5
Liu, T.6
-
128
-
-
1942506706
-
V599EB-RAF is an oncogene in melanocytes
-
C. Wellbrock, L. Ogilvie, D. Hedley, M. Karasarides, J. Martin, and D. Niculescu-Duvaz V599EB-RAF is an oncogene in melanocytes Cancer Res 64 2004 2338 2342
-
(2004)
Cancer Res
, vol.64
, pp. 2338-2342
-
-
Wellbrock, C.1
Ogilvie, L.2
Hedley, D.3
Karasarides, M.4
Martin, J.5
Niculescu-Duvaz, D.6
-
129
-
-
84875717480
-
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition
-
S.R. Whittaker, J.P. Theurillat, E. Van Allen, N. Wagle, J. Hsiao, and G.S. Cowley A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition Cancer Discov 3 2013 350 362
-
(2013)
Cancer Discov
, vol.3
, pp. 350-362
-
-
Whittaker, S.R.1
Theurillat, J.P.2
Van Allen, E.3
Wagle, N.4
Hsiao, J.5
Cowley, G.S.6
-
130
-
-
77954929373
-
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
-
W.R. Wiedemeyer, I.F. Dunn, S.N. Quayle, J. Zhang, M.G. Chheda, and G.P. Dunn Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM Proc Natl Acad Sci U S A 107 2010 11501 11506
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 11501-11506
-
-
Wiedemeyer, W.R.1
Dunn, I.F.2
Quayle, S.N.3
Zhang, J.4
Chheda, M.G.5
Dunn, G.P.6
-
131
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, and H. Rong BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
-
(2004)
Cancer Res
, vol.64
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
Wilkie, D.4
McNabola, A.5
Rong, H.6
-
132
-
-
84871390702
-
Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: A case illustrating the challenges for personalized medicine
-
J.S. Wilmott, V. Tembe, J.R. Howle, R. Sharma, J.F. Thompson, and H. Rizos Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: A case illustrating the challenges for personalized medicine Mol Cancer Ther 11 2012 2704 2708
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 2704-2708
-
-
Wilmott, J.S.1
Tembe, V.2
Howle, J.R.3
Sharma, R.4
Thompson, J.F.5
Rizos, H.6
-
133
-
-
84864286442
-
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
-
T.R. Wilson, J. Fridlyand, Y. Yan, E. Penuel, L. Burton, and E. Chan Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors Nature 487 2012 505 509
-
(2012)
Nature
, vol.487
, pp. 505-509
-
-
Wilson, T.R.1
Fridlyand, J.2
Yan, Y.3
Penuel, E.4
Burton, L.5
Chan, E.6
-
134
-
-
84856217925
-
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
-
F. Xing, Y. Persaud, C.A. Pratilas, B.S. Taylor, M. Janakiraman, and Q.B. She Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF Oncogene 31 2012 446 457
-
(2012)
Oncogene
, vol.31
, pp. 446-457
-
-
Xing, F.1
Persaud, Y.2
Pratilas, C.A.3
Taylor, B.S.4
Janakiraman, M.5
She, Q.B.6
-
135
-
-
84925604287
-
The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
-
V. Yadav, T.F. Burke, L. Huber, R.D. Van Horn, Y. Zhang, and S.G. Buchanan The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation Mol Cancer Ther 13 2014 2253 2263
-
(2014)
Mol Cancer Ther
, vol.13
, pp. 2253-2263
-
-
Yadav, V.1
Burke, T.F.2
Huber, L.3
Van Horn, R.D.4
Zhang, Y.5
Buchanan, S.G.6
-
136
-
-
84864994126
-
Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma
-
V. Yadav, X. Zhang, J. Liu, S. Estrem, S. Li, and X.Q. Gong Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma J Biol Chem 287 2012 28087 28098
-
(2012)
J Biol Chem
, vol.287
, pp. 28087-28098
-
-
Yadav, V.1
Zhang, X.2
Liu, J.3
Estrem, S.4
Li, S.5
Gong, X.Q.6
-
137
-
-
84855302859
-
Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma
-
M. Yancovitz, A. Litterman, J. Yoon, E. Ng, R.L. Shapiro, and R.S. Berman Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma PLoS One 7 2012 e29336
-
(2012)
PLoS One
, vol.7
, pp. e29336
-
-
Yancovitz, M.1
Litterman, A.2
Yoon, J.3
Ng, E.4
Shapiro, R.L.5
Berman, R.S.6
-
138
-
-
84863012433
-
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
-
H. Yang, B. Higgins, K. Kolinsky, K. Packman, W.D. Bradley, and R.J. Lee Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer Cancer Res 72 2012 779 789
-
(2012)
Cancer Res
, vol.72
, pp. 779-789
-
-
Yang, H.1
Higgins, B.2
Kolinsky, K.3
Packman, K.4
Bradley, W.D.5
Lee, R.J.6
-
139
-
-
77954376912
-
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models
-
H. Yang, B. Higgins, K. Kolinsky, K. Packman, Z. Go, and R. Iyer RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models Cancer Res 70 2010 5518 5527
-
(2010)
Cancer Res
, vol.70
, pp. 5518-5527
-
-
Yang, H.1
Higgins, B.2
Kolinsky, K.3
Packman, K.4
Go, Z.5
Iyer, R.6
-
140
-
-
0037112438
-
Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia
-
S.T. Yuen, H. Davies, T.L. Chan, J.W. Ho, G.R. Bignell, and C. Cox Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia Cancer Res 62 2002 6451 6455
-
(2002)
Cancer Res
, vol.62
, pp. 6451-6455
-
-
Yuen, S.T.1
Davies, H.2
Chan, T.L.3
Ho, J.W.4
Bignell, G.R.5
Cox, C.6
-
141
-
-
0029664339
-
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
-
L. Zuo, J. Weger, Q. Yang, A.M. Goldstein, M.A. Tucker, and G.J. Walker Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma Nat Genet 12 1996 97 99
-
(1996)
Nat Genet
, vol.12
, pp. 97-99
-
-
Zuo, L.1
Weger, J.2
Yang, Q.3
Goldstein, A.M.4
Tucker, M.A.5
Walker, G.J.6
|